Plain-English translation of NCT06751966 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a personalized tumor combined with standard third-line chemotherapy for people with colorectal cancer that has progressed after two rounds of prior treatment. The personalized vaccine is custom-made for each patient based on genetic analysis of their tumor. You would receive both the vaccine (given as 10 injections over 21 weeks) and conventional chemotherapy as your third-line treatment.
After cancer has been treated with two rounds of chemotherapy and continues to grow, treatment options become limited. This trial is testing whether adding a personalized vaccine that trains your immune system to recognize your specific tumor might help this medication work better and improve outcomes for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital for your regular chemotherapy infusions and receive 10 vaccine injections (under the skin) over a 21-week period. During and after treatment, you would have regular follow-up visits every 6 weeks that include blood tests, physical exams, and imaging scans (CT or MRI) to see how you're responding. The entire study participation would continue until the end of the study period, with close monitoring to track your health and how well the combined treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China